This vaccine induced CD4+ and CD8+ T cell responses to EBNA1 and LMP2, respectively, in patients in the United Kingdom and in Hong Kong with nasopharyngeal carcinoma (52, 53). Here, PSMB9 is linked to nasopharyngeal carcinoma.